PURPOSE: To study the outcomes in patients treated for localized prostate cancer with 70 Gy delivered at 2.5-Gy/fraction within 5 weeks. METHODS AND MATERIALS: The study sample included all 770 consecutive patients with localized prostate cancer treated with hypofractionated intensity-modulated radiotherapy at the Cleveland Clinic between 1998 and 2005. The median follow-up was 45 months (maximum, 86). Both the American Society for Therapeutic Radiology and Oncology (ASTRO) biochemical failure definition and the alternate nadir + 2 ng/mL definition were used. RESULTS: The overall 5-year ASTRO biochemical relapse-free survival rate was 82% (95% confidence interval, 79-85%), and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79-86%). For patients with low-risk, intermediate-risk, and high-risk disease, the 5-year ASTRO rate was 95%, 85%, and 68%, respectively. The 5-year nadir + 2 ng/mL rate for patients with low-, intermediate-, and high-risk disease was 94%, 83%, and 72%, respectively. The Radiation Therapy Oncology Group acute rectal toxicity scores were 0 in 51%, 1 in 40%, and 2 in 9% of patients. The acute urinary toxicity scores were 0 in 33%, 1 in 48%, 2 in 18%, and 3 in 1% of patients. The late rectal toxicity scores were 0 in 89.6%, 1 in 5.9%, 2 in 3.1%, 3 in 1.3%, and 4 in 0.1% (1 patient). The late urinary toxicity scores were 0 in 90.5%, 1 in 4.3%, 2 in 5.1%, and 3 in 0.1% (1 patient). CONCLUSION: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction.
PURPOSE: To study the outcomes in patients treated for localized prostate cancer with 70 Gy delivered at 2.5-Gy/fraction within 5 weeks. METHODS AND MATERIALS: The study sample included all 770 consecutive patients with localized prostate cancer treated with hypofractionated intensity-modulated radiotherapy at the Cleveland Clinic between 1998 and 2005. The median follow-up was 45 months (maximum, 86). Both the American Society for Therapeutic Radiology and Oncology (ASTRO) biochemical failure definition and the alternate nadir + 2 ng/mL definition were used. RESULTS: The overall 5-year ASTRO biochemical relapse-free survival rate was 82% (95% confidence interval, 79-85%), and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79-86%). For patients with low-risk, intermediate-risk, and high-risk disease, the 5-year ASTRO rate was 95%, 85%, and 68%, respectively. The 5-year nadir + 2 ng/mL rate for patients with low-, intermediate-, and high-risk disease was 94%, 83%, and 72%, respectively. The Radiation Therapy Oncology Group acute rectal toxicity scores were 0 in 51%, 1 in 40%, and 2 in 9% of patients. The acute urinary toxicity scores were 0 in 33%, 1 in 48%, 2 in 18%, and 3 in 1% of patients. The late rectal toxicity scores were 0 in 89.6%, 1 in 5.9%, 2 in 3.1%, 3 in 1.3%, and 4 in 0.1% (1 patient). The late urinary toxicity scores were 0 in 90.5%, 1 in 4.3%, 2 in 5.1%, and 3 in 0.1% (1 patient). CONCLUSION: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction.
Authors: Giuseppe Ferrera; Gianluca Mortellaro; Mariella Mannino; Giovanni Caminiti; Antonio Spera; Vanessa Figlia; Giuseppina Iacoviello; Gioacchino Di Paola; Rosario Mazzola; Antonio Lo Casto; Filippo Alongi; Maria Pia Pappalardo; Roberto Lagalla Journal: Radiol Med Date: 2015-05-24 Impact factor: 3.469
Authors: M Geier; S T Astner; M N Duma; V Jacob; C Nieder; J Putzhammer; C Winkler; M Molls; H Geinitz Journal: Strahlenther Onkol Date: 2012-02-26 Impact factor: 3.621
Authors: Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu Journal: J Clin Invest Date: 2013-09-16 Impact factor: 14.808
Authors: B A Jereczek-Fossa; A Maucieri; G Marvaso; S Gandini; C Fodor; D Zerini; G Riva; O Alessandro; A Surgo; S Volpe; G Fanetti; S Arculeo; M A Zerella; S Parisi; P Maisonneuve; A Vavassori; F Cattani; R Cambria; C Garibaldi; A Starzyńska; G Musi; O De Cobelli; M Ferro; F Nolè; D Ciardo; R Orecchia Journal: Med Oncol Date: 2018-11-27 Impact factor: 3.064
Authors: Nicholas G Zaorsky; Nitin Ohri; Timothy N Showalter; Adam P Dicker; Robert B Den Journal: Cancer Treat Rev Date: 2013-03-01 Impact factor: 12.111
Authors: Jarad M Martin; Andrew Bayley; Robert Bristow; Peter Chung; Mary Gospodarowicz; Cynthia Menard; Michael Milosevic; Tara Rosewall; Padraig R Warde; Charles N Catton Journal: Radiat Oncol Date: 2009-11-03 Impact factor: 3.481
Authors: Simona Marzi; Biancamaria Saracino; Maria G Petrongari; Stefano Arcangeli; Sara Gomellini; Giorgio Arcangeli; Marcello Benassi; Valeria Landoni Journal: J Exp Clin Cancer Res Date: 2009-08-19